Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Am Acad Dermatol ; 83(6): 1590-1598, 2020 Dec.
Article in English | MEDLINE | ID: mdl-30576759

ABSTRACT

BACKGROUND: Tumor necrosis factor-α (TNF-α) inhibitor (TNFI)-induced psoriasis remains poorly understood despite having been described 15 years ago. As TNFIs often provide life-changing patient benefits, understanding effective treatments for TNFI-induced psoriasis is important. OBJECTIVE: We characterized a cohort of patients with TNFI-induced psoriasis whose psoriasis was specifically diagnosed and managed or comanaged by dermatologists at a single tertiary care institution over a 10-year period. METHODS: Retrospective review of patients in whom TNFI-induced psoriasis was diagnosed between 2003 and 2013. RESULTS: A total of 102 patients with TNFI-induced psoriasis were identified. The mean age of onset was 40 years, and there was a female predominance (73.5%). Crohn's disease (in 48% of cases) and rheumatoid arthritis (in 24.5% of cases) were the most common primary conditions. Infliximab (in 52% of cases) was the most common inciting agent. The most common TNFI-induced psoriasis subtypes were plaque-type psoriasis (49.5%), scalp psoriasis (47.5%), and palmoplantar pustulosis (41%). Topical medications alone improved or resolved TNFI-induced psoriasis in 63.5% of patients, and cyclosporine and methotrexate (>10 mg weekly) were often effective if topicals failed. Discontinuation of the inciting TNFI with or without other interventions improved or resolved TNFI-induced psoriasis in 67% of refractory cases, whereas switching TNFIs resulted in persistence or recurrence in 64%. LIMITATIONS: Retrospective nature of the study and the fact that some patients may have developed typical psoriasis unresponsive to TNFIs. CONCLUSION: Our study cohort represents the largest single-institution cohort of patients with TNFI-induced psoriasis diagnosed and managed or comanaged by dermatologists to date. On the basis of our findings, we propose a treatment algorithm for TNFI-induced psoriasis.


Subject(s)
Antirheumatic Agents/adverse effects , Immunosuppressive Agents/administration & dosage , Psoriasis/epidemiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Child , Cyclosporine/administration & dosage , Female , Humans , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/immunology , Male , Methotrexate/administration & dosage , Middle Aged , Psoriasis/chemically induced , Psoriasis/drug therapy , Psoriasis/immunology , Recurrence , Retrospective Studies , Risk Factors , Sex Factors , Spondylitis, Ankylosing/drug therapy , Spondylitis, Ankylosing/immunology , Treatment Outcome , Tumor Necrosis Factor-alpha/immunology , Young Adult
2.
J Am Acad Dermatol ; 83(6): 1599-1605, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32592879

ABSTRACT

BACKGROUND: Tumor necrosis factor-α inhibitor-induced psoriasis (TNFI psoriasis) is a paradoxical reaction characterized by development of a psoriasiform rash that mimics psoriasis vulgaris. Temporal onset variability and low incidence rates suggest that underlying risk factors or outside triggers have a role in TNFI psoriasis initiation. OBJECTIVES: We aimed to identify underlying risk factors and outside triggers associated with TNFI psoriasis onset. METHODS: This case-control study included 97 patients at a tertiary care center between 2003 and 2013 who developed TNFI psoriasis. Ninety-seven control patients were matched to age, sex, disease, TNF-α inhibitor, and length of time on treatment before TNFI psoriasis onset. Patient medical records were reviewed ≥6 months immediately preceding TNFI psoriasis onset (similar equivalent time point for matched controls) for information about potential risk factors and outside factors categorized as: (1) serologic abnormalities, (2) acute events, and (3) social factors. RESULTS: Compared with those of matched controls, odds ratios (ORs) were significantly higher in the TNFI psoriasis group for psoriasis family history (OR, 16.0) and acute psychological stressors (OR, 3.14) and marginally associated with tobacco use (OR, 1.76). CONCLUSIONS: Our results suggest that psoriasis family history, psychological stressors, and tobacco use might be risk factors for developing TNFI psoriasis. Performing detailed patient histories when considering TNFI therapy may be useful in identifying patients at risk for TNFI-psoriasis.


Subject(s)
Antirheumatic Agents/adverse effects , Psoriasis/epidemiology , Stress, Psychological/complications , Tobacco Smoking/epidemiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Age of Onset , Case-Control Studies , Disease Susceptibility/immunology , Disease Susceptibility/psychology , Humans , Incidence , Medical History Taking , Middle Aged , Psoriasis/chemically induced , Psoriasis/immunology , Risk Factors , Sex Factors , Stress, Psychological/immunology , Stress, Psychological/psychology , Time Factors , Tobacco Smoking/immunology , Tumor Necrosis Factor-alpha/immunology , Young Adult
4.
Skin Appendage Disord ; 10(2): 99-103, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38572193

ABSTRACT

Background: Gout is a depositional, inflammatory disorder that is rarely reported to affect the nail unit. Cases of gout involving the nail unit are likely under-recognized and therefore underreported. We present two cases of tophaceous gout affecting the nail unit and a literature review of the various presentations. Summary: Five cases of gout were identified to affect the nail unit. In all cases, these presented as white hyperkeratotic papulonodules with associated nail dystrophy. Chalky discharge was seen in three of the five cases. Nine cases were identified to have demonstrated pseudocarcinomatous changes that histopathologically mimic squamous cell carcinoma (SCC). Literature review highlights a range of findings including subclinical deposits of uric acid in the nail, onychoschizia, onychorrhexis, and Beau's line. Key Messages: Physicians should be aware of the subtle and nonspecific clinical findings of gout, which may be easily misconstrued for other pathological entities.

5.
J Vasc Surg ; 53(5): 1394-7, 2011 May.
Article in English | MEDLINE | ID: mdl-21276686

ABSTRACT

Sarcomas of the large vessels usually present centrally in the aorta, pulmonary artery, and inferior vena cava. Peripheral arterial sarcomas are exceptionally rare. They have been reported in the iliac and common or profunda femoral arteries, and are frequently undifferentiated. In this study, we describe a differentiated intimal sarcoma of the superficial femoral artery with abundant osteosarcoma within the specimen. Before knowing the diagnosis, treatment was for a presumed pseudoaneurysm using excision and bypass. Postoperatively, the patient received palliative radiation therapy. The tumor's location and histopathology are unique. A differentiated intimal sarcoma has never been reported in the superficial femoral artery, and it represents the second peripheral arterial intimal sarcoma reported with osteosarcomatous differentiation.


Subject(s)
Cell Differentiation , Femoral Artery/pathology , Osteosarcoma/pathology , Sarcoma/pathology , Tunica Intima/pathology , Vascular Neoplasms/pathology , Aged, 80 and over , Aneurysm, False/diagnosis , Biopsy , Diagnostic Errors , Fatal Outcome , Femoral Artery/radiation effects , Femoral Artery/surgery , Humans , Immunohistochemistry , Magnetic Resonance Angiography , Osteosarcoma/therapy , Palliative Care , Radiotherapy, Adjuvant , Sarcoma/therapy , Treatment Outcome , Tunica Intima/radiation effects , Tunica Intima/surgery , Vascular Neoplasms/therapy , Vascular Surgical Procedures
SELECTION OF CITATIONS
SEARCH DETAIL